August 27, 2013 – A panel of judges has ruled to consolidate all federal pancreatic cancer lawsuits involving the diabetes drugs Byetta, Januvia, Janumet, and Victoza into a multidistrict litigation (MDL) for pretrial handling in the Southern District of California. These medications all belong to a class of drugs known as incretin mimetics, which have recently been linked to pancreatitis, pancreatic cancer, and thyroid cancer. Consolidation is commonly implemented in complex pharmaceutical litigation where a large number of claims are filed involving similar allegations.
Free Diabetes Drug Pancreatic Cancer Lawsuit Evaluation: If you or a loved one has been diagnosed with pancreatic cancer after taking Byetta, Januvia, Janumet, or Victoza, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against and our lawyers can help.
Incretin Mimetics Product Liability Litigation
On August 26, it was decided that the ‘Incretin Mimetics Product Liability Litigation’ would be centralized before U.S. District Judge Anthony J. Battaglia in the Southern District of California. There are now at least 53 pancreatic cancer lawsuits involving Byetta (exenatide), Januvia (sitagliptin), Janumet (metformin and sitagliptin), and Victoza (liraglutide) in seven different districts, the vast majority of which are already pending in California. These complaints involve allegations that the drugs’ manufacturers failed to adequately research their products before bringing them to market, and were negligent for not warning the public and medical communities about their potential to cause pancreatic cancer.
Consolidation is used to reduce duplicative discovery, avoid conflicting rulings by different judges, and to speed things through the litigation process as quickly as possible. However, over the past several years, separate proceedings have been established for lawsuits involving different pharmaceutical companies. In this case, all parties involved called for the litigation to be centralized in a single jurisdiction, as many plaintiffs have taken more than one of the diabetes drugs before being diagnosed with pancreatic cancer.
“Plaintiffs in the cases now before us, however, make highly similar allegations about each of the four drugs that manage blood insulin levels and the propensity of those drugs to cause pancreatic cancer,” the Judicial Panel on Multidistrict Litigation wrote. “Several plaintiffs took more than one of the drugs at issue, which suggests that discovery specific to the plaintiffs in those cases will involve many of the same or substantially similar documents and witnesses.”
The Byetta pen was the first incretin mimetic to hit the U.S. market in 2005. The Following year, Merck released Januvia followed by Janumet in 2007. Victoza, an injectable incretin mimetic, was approved by the U.S. Food & Drug Administration (FDA) in 2010.
Do I Have a Diabetes Drug Pancreatic Cancer Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in diabetes drug lawsuits. We are handling individual litigation nationwide and currently accepting new pancreatic cancer cases in all 50 states.
Free Confidential Case Evaluation: If you or a loved one has been diagnosed with pancreatic cancer after taking Byetta, Januvia, Janumet or Victoza, you should contact our law firm immediately. You may be entitled to compensation by filing a class action suit and our lawyers can help.